Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

Constipation reduces desmopressin efficacy in children with nocturnal enuresis

30 Dec 2018

Treatment response to desmopressin for paediatric nocturnal enuresis (NE) decreases in the presence of constipation, especially in children with severe enuresis and those prescribed with low-dose desmopressin, a study has shown.

Researchers looked at 383 patients (52.7 percent boys) with NE aged 5–15 years, among whom 54 (14 percent) presented with constipation. The majority of patients (76.0 percent) had severe enuresis, and the incidence of severe enuresis in the group of patients with constipation was higher than that in the nonconstipation group (94.4 percent vs 72.9 percent; p=0.001).

In the cohort, only 346 children completed desmopressin treatment. Complete response rate was significantly lower in the presence of constipation in the group of patients with severe enuresis. Constipation was associated with the effectiveness of desmopressin whether in monosymptomatic or nonmonosymptomatic NE.

In an analysis stratifying by dose of desmopressin, nonconstipated vs constipated patients who received 0.2 mg had significantly higher complete response rate. However, in subgroups of mild-to-moderate NE and 0.4 mg desmopressin, constipation showed no association with treatment response.

Multivariate logistic regression revealed constipation to be an independent risk factor for the efficacy of desmopressin in treating enuresis (odds ratio, 3.135; 95 percent CI, 1.185–8.295; p=0.021).

The present data suggest that complete response could be likely expected in children without constipation, researchers said. Additional studies with large sample size and are needed to verify the association between constipation and desmopressin efficacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.